Effects of lovastatin on breast cancer cells: a proteo-metabonomic study by Klawitter, Jelena et al.
RESEARCH ARTICLE Open Access
Effects of lovastatin on breast cancer cells:
a proteo-metabonomic study
Jelena Klawitter
1*, Touraj Shokati
1, Vanessa Moll
1, Uwe Christians
1, Jost Klawitter
1,2
Abstract
Introduction: Statins are cholesterol-lowering drugs with pleiotropic activities including inhibition of isoprenylation
and reduction of signals driving cell proliferation and survival responses.
Methods: In this study we evaluated the effects of lovastatin acid and lactone on breast cancer MDAMB231 and
MDAMB468 cells using a combination of proteomic and metabonomic profiling techniques.
Results: Lovastatin inhibited proliferation of breast cancer cell lines. MDAMB231 cells were more sensitive to its
effects, and in most cases lovastatin acid showed more potency towards the manipulation of protein expression
than lovastatin lactone. Increased expression of Rho inhibitor GDI-2 stabilized the non-active Ras homolog gene
family member A (RhoA) leading to a decreased expression of its active, membrane-bound form. Its downstream
targets cofilin, CDC42 and G3BP1 are members of the GTPase family affected by lovastatin. Our data indicated that
lovastatin modulated the E2F1-pathway through the regulation of expression of prohibitin and retinoblastoma (Rb).
This subsequently leads to changes of E2F-downstream targets minichromosome maintenance protein 7 (MCM7)
and MutS homolog 2 (MSH2). Lovastatin also regulated the AKT-signaling pathway. Increased phosphatase and
tensin homolog (PTEN) and decreased DJ-1 expression lead to a down-regulation of the active pAkt. Lovastatin’s
involvement in the AKT-signaling pathway was confirmed by an upregulation of its downstream target, tumor
progressor NDRG1. Metabolic consequences to lovastatin exposure included suppression of glycolytic and Krebs
cycle activity, and lipid biosynthesis.
Conclusions: The combination of proteomics and metabonomics enabled us to identify several key targets
essential to the antitumor activity of lovastatin. Our results imply that lovastatin has the potential to reduce the
growth of breast cancer cells.
Introduction
Breast cancer is the second leading cause of cancer
death in women. There are currently no effective thera-
pies for advanced breast cancer, with treatment primar-
ily aimed at palliation of symptoms and improvement of
overall survival. Healthy women at high risk of breast
cancer are the focus of prevention, whereas current che-
motherapy targets women after a positive diagnosis. Pre-
v e n t i o ni na tr i s k ,b u th e a l t h y ,w o m e nr e q u i r e s
efficacious drugs with a good long-term safety and toler-
ability profile. Statins fit these criteria [1-6].
Statins are competitive inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme reductase (HMG-CoA). They
reduce cholesterol synthesis by blocking the conversion
of HMG-CoA to mevalonate [7]. The end products of
the mevalonate pathway are required for a number of
essential cellular functions. The end products include:
sterols, involved in membrane integrity and steroid pro-
duction; ubiquinone (coenzyme Q), involved in electron
transport and cell respiration; farnesyl and geranylgera-
nyl isoprenoids, involved in covalent binding of proteins
to membranes; dolichol, which is required for glycopro-
tein synthesis; and isopentenyladenine, essential for cer-
tain tRNA functions and protein synthesis [8,9].
HMG-CoA reductase inhibitors have been shown to
inhibit cellular proliferation and induce apoptosis and
necrosis in several experimental settings including that
of breast cancer, thus making them potential anticancer
agents [10-12]. Induction and enhancement of reactive
oxygen species (ROS) formation has been explored as a
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cells [13]. Stimulation of nitric oxide synthase (iNOS)
and the subsequent increase in nitric oxide (NO) levels
may also play a role in the pro-apoptotic and anti-prolif-
erative effects of statins on breast cancer cells [14]. Sev-
eral cell signaling pathways seem to be involved in the
inhibition of cell proliferation and statin-induced cancer
cell death, including FAK/ERK pathways [15], increased
expression of p21, p27 and activated caspase-3, and
changes in the expression of several cyclin-dependent
kinases [16].
Recent clinical data show that statins may influence
the phenotype of breast tumors, suggesting a new
potential strategy for breast cancer prevention, that of
combining statins with agents that prevent estrogen
receptor (ER)-positive cancer (tamoxifen, aromatase
inhibitors) [1]. Another study suggested statin treatment
following breast cancer diagnosis decreases the risk of
recurrence, and a further decline in correlation to the
duration of statin use [2]. Lovastatin is orally adminis-
tered to patients in its lactone form. However, after
absorption, lovastatin is quickly converted into its open
acid form and, as with most statins, lovastatin is present
in plasma as the active acid that is responsible for
HMG-CoA inhibition and two orders of magnitude
more lipophilic lactone. As both forms have distinct
physicochemical properties and potentially different
mechanisms of action, both are studied here.
In order to gain more insight into the anticancer
activity and mechanism of action of statins in breast
cancer cells, our study employed a combination of pro-
teomics-based and nuclear magnetic resonance (NMR)-
based metabonomics techniques. We identified new key
targets of lovastatin, and revealed involvement of several
regulatory cellular pathways in the cytotoxic effects of
lovastatin on breast cancer cell lines.
Materials and methods
Reagents
Tris-HCl, sodium chloride, EDTA, NP-40, sodium deox-
y c h o l a t e ,u r e a ,t h i o u r e a ,S D S ,2 0 %g l y c e r o l ,m e t h a n o l ,
acetic acid and iodacetamide were purchased from
Sigma-Aldrich (Allentown, PA, USA). Protease and
phosphate inhibitors were from Pierce Biotechnology
(Rockford, IL, USA); immobilized pH gradient (IPG)
buffer pH 3 to 11 was from GE Healthcare (Piscataway,
NJ, USA) and dithiothreitol (DTT) was from USB (Cle-
veland, OH, USA). Lovastatin (in its lactone and
hydroxy acid form) was purchased from Toronto
Research Chemicals (North York, Ontario, Canada). 3-
(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bro-
mide (MTT) cell growth assay kits were from Millipore
(Billerica, MA, USA).
Cell culture and treatments
MDAMB468 and MDAMB231 cell lines were from
American Type Culture Collection (ATCC) and propa-
gated according to the instructions provided. Both cell
lines are ER negative, and for this study relevant differ-
ences were that MDAMB468 cells lack expression of
retinoblastoma (Rb), phosphatase and tensin homolog
(PTEN) and steroid and xenobiotic receptor (SXR)
proteins.
For proteomics studies, cells were treated for 48 hours
with 8 μg/mL lovastatin lactone or hydroxy acid. MTT
assays were performed prior to proteomics studies for
IC50 determination. To investigate the effects of isopre-
noid intermediates of the cholesterol biosynthetic path-
way, in particular geranylgeranyl diphosphate (GGPP),
farnesyl pyrophosphate (FPP) and mevalonic acid on the
proliferation of cells treated with lovastatin,
MDAMB231 and MDAMB468 cells were treated with
2 μg/mL, 4 μg/mL and 8 μg/mL lovastatin acid or lac-
tone and were ‘rescued’ by addition of 10 μM GGPP,
100 μM mevalonic acid or 10 μM FPP.
MTT assay
The cells were cultured in 96-well plates. Treatment
occurred with lovastatin in its lactone or acid form or
with a combination of lovastatin with GGPP, FPP or
mevalonic acid for 48 hours. During the last four hours,
0.02% MTT solution was added and the reaction was
stopped with isopropanol and 5% acetic acid. The pro-
d u c t i o no fp u r p l ef o r m a z a ni nc e l l st r e a t e dw i t ha n
agent was measured relative to the production in con-
trol cells and dose-response curves were generated with
a Perkin Elmer (Waltham, MA, USA) ELISA plate
reader at 525 nm.
IC50 values were estimated using the Prism software
(GraphPad Software Inc., Version 4.0, San Diego, CA,
USA).
Two-dimensional gel electrophoresis
For proteomics studies, cells were washed twice with
ice-cold PBS followed by a collection in modified RIPA
l y s i sb u f f e r( 5 0m MT r i s - H C l ,p H7 . 4 ;1 5 0m MN a C l ;1
mM EDTA; 1% NP-40 (v/v); 0.25% sodium deoxycholate
(v/v); protease and phosphatase inhibitor cocktail). After
complete solubilization, cell extracts were subjected to
purification using a 2-D clean-up kit (GE Healthcare,
Piscataway, NJ, USA) in accordance with the manufac-
turer’s instructions. The final solubilization was per-
formed in chaotropic lysis buffer containing 7 M urea, 1
M thiourea, 50 mM DTT, 0.4% IPG buffer pH 4 to 7,
protease and phosphatase inhibitors. The protein con-
centrations were determined using a BioRad Bradford
protein assay kit (BioRad, Hercules, CA, USA). Samples
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biline DryStrips (11 cm, pH 3 to 8, GE Healthcare, Piscat-
away, NJ, USA). Isoelectric focusing was performed on a
Protean IEF cell (Biorad, Hercules, CA, USA) with the fol-
lowing voltage program: rehydration: 50 V, 12 hours; 1000
V, 2 hours (gradient); 6000 V, 4 hours (gradient); 8000 V,
6 hours (rapid), maximal current 50 uA per strip. Strips
were equilibrated in 20 mL rehydration buffer (6 M urea,
50 mM Tris-HCl pH 8.8, 2% SDS, 20% v/v glycerol) con-
taining 10 mg/mL DTT and 25 mg/mL iodacetamide for
20 minutes each. The second dimension was performed
using a Mini-Protean Dodeca chamber (Biorad, Hercules,
CA, USA) on 10.5 to 14% Criterion Tris-HCl gels (IPG +
1 well, 11 cm, Biorad, Hercules, CA, USA). Gels were
washed with nanopure water and with Biosafe Coomassie-
Blue Stain (Biorad, Hercules, CA, USA) or fixed for one
hour in 50% methanol, 10% acetic acid and stained with
Sypro Ruby protein gels stain (Invitrogen, Carlsbad, CA,
USA) overnight. Prior to imaging Coomassie-Blue stained
gels were washed in nanopure water for up to 24 hours
and imaged on LabScan Image Scanner (GE Healthcare,
Piscataway, NJ, USA) with 900 dpi. Sypro Ruby-stained
gels were washed twice in 10% methanol and 7% acetic
acid for one hour each and imaged on a Typhoon 8600
imager (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) with 532 nm laser wavelength.
Gel image analysis was carried out using the Image-
Master 2D Platinum II software version 5.0 (GE Health-
care, Piscataway, NJ, USA). The spot auto-detect
function was used for all group comparisons using iden-
tical parameters. Groups were matched automatically
and corrected manually if necessary. Differences in pro-
tein expression were identified using the relative volume
(%Vol) option of the software. This option allows the
data to be independent of experimental variations
between gels caused by differences in loading or stain-
ing. Relative volume was calculated as follows [17,18]:
%  Vol  100 Vol
s Vol s1
n 
  with Vols being the volume
of spot s in a gel containing n spots.
Raw spot values were normalized using the software’s
ratio option according to the following equation [17-19]:
Rat i o
spot   val uess
cent r al   t endency  with central tendency being
the mean of spot s.
Changes in average volume larger than ± 40% of the
a v e r a g es p o tv o l u m ea n dt h es i g n i f i c a n c el e v e lo fP <
0.05 (control vs. treated group) was the criterion used
for excision. Four replicates were used for each control,
lovastatin lactone or acid treatment, respectively.
In-gel digestion
Proteins from excited gels spots were digested using a
modification of the method by Havlis [20]. Briefly, spots
were destained with acetonitrile and 100 mM ammonium
bicarbonate (50/50 v/v), contracted with 100% acetoni-
trile and then vacuum dried. Spots were rehydrated with
50 μg/ml trypsin (sequencing grade II, Worthington,
Lakewood, NJ, USA) and incubated for 10 minutes on
ice. Excess liquid was removed and 50 mM ammonium
bicarbonate added prior to overnight incubation at 37°C.
The supernatants were collected and pooled with two
additional extracts using 1% formic acid with 30% aceto-
nitrile. Pooled extracts were vacuum concentrated to
approximately 10 μL and stored at -80°C until mass spec-
trometry analysis.
LC-MS/MS analysis of tryptic digests
The analysis of tryptic digests was performed using a
4000 QTRAP liquid chromatography (LC) mass spectro-
metry (MS)/MS system (Applied Biosystems, Foster City,
CA, USA) equipped with a Dionex Ultimate 3000 nano-
LC system (Dionex Corporation, Sunnyvale, CA, USA).
Peptides were loaded onto an enrichment column
(C18PM, LC packings 0.3 mm ID) with 3% acetonitrile
(ACN) and 0.05% trifluoroacetic acid (TFA) at a flow
rate of 4 μL/min. After activation of a switching valve,
the peptide mixture was back-flushed from the enrich-
ment onto the analytical column (Zorbax 300SB C18,
3.5 um, 150 × 75, Agilent Technologies, Palo Alto, CA,
USA) using a gradient. Solvent A was 0.1% formic acid
and solvent B was 80% CAN and 0.1% formic acid. The
flow rate was 400 nL/min. Buffer B was increased from
5% to 8% in one minute and then from 8% to 45% over
39 minutes. Finally, solvent B was increased to and held
at 80% for the next five minutes, after which the settings
were returned to initial conditions. Spectra were col-
lected over an m/z range of 350 to 2200 Da. Three MS/
MS spectra were collected for the three most abundant
m/z values. Then those were excluded from analysis for
one minutes and the next three most abundant m/z
values were selected for fragmentation.
Protein identification using database searching
Proteins were identified by searching the databases of
the NCBInr (National Center for Biotechnology Infor-
mation, non-redundant) and SwissProt (Swiss Institute
of Bioinformatics) using ProteinPilot 2.0 with paragorn
algorithm (Applied Biosystems, Foster City, CA, USA)
software. Parameters used in the database search were
as follows: biological modifications; fixed modification:
iodacetamide alkylation of Cys; detected protein thresh-
old: more than 1 (90%); thorough ID.
Cell extraction for nuclear magnetic resonance
spectroscopy
For NMR experiments, the cells were incubated with 5
mmol/L (1-
13C) glucose (Cambridge Isotope Laboratories,
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perchloric acid (PCA) extraction. All cell extractions were
performed using a previously published PCA extraction
protocol that allowed for separation of water-soluble and
lipid fractions [21]. Lyophilized water-soluble cell extracts
were re-dissolved in 0.5 mL of deuterium oxide, centri-
fuged and the supernatants neutralized to pH 7.2 in order
to allow for precise chemical shift assignments. Lipid frac-
tions were re-dissolved in a 1 mL CD3OD/CDCl3 mixture
(1:2).
NMR spectroscopy
High-resolution
1Ha n d
13C-NMR experiments were
performed using a Varian INOVA NMR 500 MHz spec-
trometer equipped with a 5 mm HCN PFG probe (Var-
ian, Palo Alto, CA, USA). For
1H-NMR analysis of
water-soluble extracts we have used fully relaxed spectra
with a standard water presaturation pulse program,
whereas for analysis of lipids no presaturation pulse was
used. Spectra were obtained at 12 ppm spectral width
(10 ppm for lipids), 32 K data arrays, and 64 scans with
90-degree pulses applied every 14.8 seconds. The pool
size of metabolites was determined based on fully
relaxed
1H-NMR spectra of extracts using trimethylsilyl
propionic-2,2,3,3,-d4 acid (TSP) as an external standard
and chemical shift reference (0 ppm). The absolute con-
centrations of each metabolite [metabolite] were deter-
mined and normalized according to cell wet weight, as
previously described [22-24] and calculated using the
following equation:
[] { [ ] } / [ * metabolite integral TSP V integral wet weigh met S TSP     t t]
where integralmet is integral of respective metabolite
signal divided by the number of protons; integralTSP is
integral of TSP signal divided by the number of protons;
[TSP] is TSP nominal concentration; VS is sample
volume; wet weight is sample weight.
13C-NMR spectra with proton decoupling (compo-
site pulse decoupling) were recorded using the C3-lac-
tate peak at 21 ppm as chemical shift reference
(spectral width was 150 ppm, 16 K data arrays, with
20 K scans applied every three seconds). For quantifi-
cation of absolute concentrations of
13C metabolites,
calculations were made according to [25,26]. The
13C-
enrichments in C3-lactate were determined by the
heteronuclear spin-coupling pattern in
1H-NMR spec-
tra as follows:
13 1 13 1 12 C enrichment area H C 100 area H C a     
 

        /        r rea H C 11 3     
 

 
where the sum (area [
1H-
12C] + area [
1H-
13C]) is
equivalent to the pool size of lactate. The values were
corrected for 1.1% natural abundance
13C.
13C-enrich-
ments in individual carbons of amino acids were derived
from
13C-NMR spectra using the known
13C-enrichment
in lactate:
E A A Met A Met 1 1 Met Met n a n a %[– ] / . .. ..           ] 
where AMet represents
13C carbon peak area of the
metabolite, An.a. is its natural abundance signal intensity,
and 1.1 is the percentage factor of the
13C-isotope. The
natural abundance of
13C, contributing to the total
intensity An.a. (Met), was determined using the known
13C-enrichment and natural abundance of lactate and
correction for the pool size:
A Met A Met E 1 Lac n.a Lac Lac () { [] }/{ ( ) [ ] }   
ALac represents the carbon peak area of lactate, [Lac]
or [Met] are the pool sizes of lactate or metabolite of
interest, respectively, and ELac is the percentage
13C-
enrichment in lactate. The
13C signal intensities were
corrected for nuclear Overhauser enhancement effects
by comparison with the standard mixture of amino
acids.
The absolute amount of
13C in specified carbon posi-
tions is the product of the pool size multiplied by the
fractional
13C-enrichment.
Western blot analysis
Western blot analysis was carried out to validate proteo-
mics ‘hits’. Aliquots of frozen extracts were loaded onto
Biorad 4 to 12% Bis-Tris Criterion gels and proteins
separated using a Biorad Criterion cell electrophoresis
system (BioRad, Hercules, CA, USA) operating for
approximately two hours at 120 V and then transferred
(200 mA, 5 hours) from the gel to an Immobilon-P
membrane (Millipore Corporation, Billerica, MA, USA).
Membranes were incubated overnight at 4°C with the
primary antibody following blocking with 5% milk/BSA
in PBS-Tween buffer. Antibodies used in this study
included: proliferating cell nuclear antigen (PCNA), pro-
hibitin, E2F-1, RhoGDI, Ras homolog gene family mem-
ber A (RhoA), pRb, cell division cycle 42 (CDC42),
PTEN (Cell Signaling Technology, Inc., Danvers, MA,
USA); high-mobility group protein B1 (HMGB1), N-myc
downstream regulated gene 1 (NDRG1), DJ-1, pAkt
(Abcam, Cambridge, MA, USA); MutS homolog 2
(MSH2), phospho-GTPase activating protein binding
protein 1 (G3BP1), pG3BP1 (GenScript, Piscataway, NJ,
USA); minichromosome maintenance protein 7
( M C M 7 )( B i o l e g e n d ,S a nD i e g o ,C A ,U S A ) .A f t e rt h e
membranes were washed three times, the secondary
antibody (horseradish peroxidase (various hosts), Pierce,
Rockford, IL, USA) was applied for three hours at room
temperature. Membranes were subsequently treated
with Pierce SuperSignal® West Pico Solution (Pierce,
Rockford, IL, USA) in accordance with the method
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maging Systems UV detector (BioImaging Systems,
Upland, CA, USA) was used to detect the horseradish
peroxidase reaction on the membrane. Densitometry
data were normalized by the amount of b-actin.
Statistical analysis
All numerical data is presented as mean ± standard
deviation from replicate experiments. Student’s t test, or
when applicable one-way analysis of variance (ANOVA)
were used to determine differences between groups.
Tukey’s test was used as a post-hoc test in combination
with ANOVA to test for significances among groups.
The significance level was set at p < 0.05 for all tests
(SigmaPlot-version 11.0, Systat Software, Point Rich-
mond, CA, USA) and PASW version 18.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Lovastatin inhibits cell proliferation
Lovastatin induces inhibition of cell proliferation in
MDAMB468 and MDAMB231 cells (Figure 1). The
lovastatin hydroxy acid form was slightly more effective
in both cell lines with a half maximum inhibition con-
centration (IC50)o f8μg/mL in MDAMB468 and 5 μg/
mL in MDAMB231 cells, whereas the IC50 values for
lovastatin lactone were 9 μg/mL and 7 μg/mL, respec-
tively. All subsequent experiments were carried out
using 8 μg/mL lovastatin in its lactone or acid form.
In rescue experiments, when cells were co-incubated
with lovastatin and GGPP, FPP or mevalonate, only
mevalonate and GGPP were able to fully rescue cells
from the anti-proliferative effect of lovastatin, whereas
FPP could only achieve a partial rescue. Upon GGPP
and mevalonate co-exposure with 8 μg/mL lovastatin
(acid or lactone), cells regained 92 to 98% of the prolif-
eration rate of control cells, whereas only 67% was
regained with the co-administration of lovastatin and
FPP.
Two-dimensional gel electrophoresis and MS analysis of
lovastatin-induced changes in the protein expression of
breast cancer cells
In order to obtain a comprehensive view of changes in
the protein synthesis in response to lovastatin treatment,
proteome analyses using two-dimensional gel electro-
phoresis were performed on MDAMB468 and
MDAMB231 breast cancer cell lines (Figure 2). Both
forms of lovastatin (lactone and hydroxy acid form with
8 μg/mL for 48 hours) were used for cell treatment.
Functional classification of identified proteins
Each identified protein was assigned a functional classifi-
cation based on the gene ontology annotation in the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID). The DAVID annotation tool was
used for functional clustering and pathway mapping of
identified protein hits. A comparison between the
expressional changes of spots in the lactone or hydroxy
acid group revealed that both chemical forms of lovasta-
tin followed the same directional change through an
increase or decrease in the relative protein abundance.
For this reason, we combined the treatment groups and
these combined protein hits were then subjected to
DAVID annotation tool analysis.
Seventy-four proteins were identified as significantly
changed upon treatment with 8 μg/mL lovastatin (lac-
tone or acid form) in MDAMB231 cells, and 42 such
proteins were identified in MDAM468 cells (Table 1).
Despite the stronger response of MDAMB231 cells,
impact by lovastatin on the biological processes was
similar in both cell lines. For example, the addition of
lovastatin not only influenced the major metabolic cellu-
lar pathways, such as glycolysis or pentose-phosphate
shunt, it also changed expression of proteins involved in
the regulation of apoptosis, stress response, cell differen-
tiation and actin-filament morphogenesis. Furthermore,
lovastatin lactone and acid exposure-induced changes in
cell cycle regulatory proteins and small GTPases
mediated signal transduction members.
Small GTPases mediated signal transduction
Small GTPase family members, some of which are
known to modulate Ras protein signal transduction,
have been described in the literature as major targets of
statins other than HMG-CoA reductase [27,28].
Our proteomics data revealed a decrease in total
expression of RhoA (Table 1). In addition to the total
expression, a western blot analysis on membrane-bound,
geranylgeranylated RhoA in MDAMB231 cells was per-
formed and it was found that lovastatin acid caused a
significant decrease in the expression of this activated
RhoA form, and that only a slight decrease was caused
by the lactone (Figure 3). Our data also showed that the
expression of GDP dissociation inhibitor 2 (GDI-2), a
protein stabilizing the inactive RhoA form, experienced
a significant increase and was more pronounced in
MDAMB231 than in MDAMB468 cells (Figure 3).
Lovastatin also induced downregulation of unmodified
and G3BP1 (Table 1, Figures 2a and 3; down-regulation
of phospho-G3BP1 only with lovastatin lactone) and
cofilin 1/2 proteins (Figure 2a), and an overexpression
of CDC42 protein (Figure 3).
Inhibition of cell proliferation and cell-cycle activity
Several proteins present in breast cancer cells that are
involved in regulation of cell proliferation and cell-cycle
activity were significantly altered when exposed to
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Page 5 of 20Figure 1 Cell proliferation of human breast cancer cell lines. (a) MDAMB231 and (b) MDAMB468. Cells were treated with increasing
concentrations of lovastatin lactone or lovastatin acid (μg/mL) for 48 hours. Data are presented as mean ± standard deviation (n = 5) *P < 0.05;
**P < 0.05; ***P < 0.001.
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ity related cell-cycle regulatory proteins prohibitin and
MCM7, were also detected. Although the expression of
prohibitin increased nearly two-fold (Table 1 and Figure 4),
the expression of MCM7, an essential component of the
replication helicase complex [29], decreased to 28% of con-
trol (Table 1 and Figure 3). Lovastatin-induced DNA
damage also had an impact on damage repair regulating
pathways. We observed a downregulation of a representa-
tive member of DNA-mismatch repair (MMR) systems,
MSH2 (Figure 4 and Table 1). Expression of PCNA is
downregulated by both forms of lovastatin in MDAMB231
cells, with a stronger reduction in presence of the lactone
form (Table 1 and Figure 5).
Figure 2 Changes in expression of proteins involved in (a) regulation of cell cycle and cell death and (b) oxidative and metabolic
processes of human MDAMB231 and MDAMB468 cells. Both cell lines were treated with 8 μg/mL lovastatin lactone (Lova Lac) or lovastatin
acid (Lova Ac) for 48 hours. Data represent relative spot volumes (as calculated from two-dimensional gel images of whole cell extracts; data are
presented as mean ± standard deviation (n = 5) *P < 0.05;**P < 0.05; ***P < 0.001). Gel spots which showed significant differences in their
volume between the control and lovastatin-treated cells were cut-out, proteins were digested and analyzed using liquid chromatography (LC)
mass spectrometry (MS)/MS analysis. In MDAMB231 cells they were identified as GTPase-activating protein SH3-domain-binding protein 1
(G3BP1), TNF type 1 receptor-associated protein (TRAP1) and glutathione S-transferase (GST) omega proteins (Table 1a), whereas the spot
belonging to citrate lyase beta and sterol carrier protein 2 (SCP-2) originated from MDAMB468 cells (Table 1b). Cofilin1/2 was identified as
upregulated in both cell lines. The image and changes as observed in MDAMB231 cells is shown.
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MDAMB231 breast cancer cells
MDAMB468 cells Control vs. lactone Control vs. acid
14-3-3 beta 3.51 1.93
14-3-3 zeta/theta 1.61 1.48
17-beta hydroxysteroid dehydrogenase 0.62 0.47
6-phosphogluconolactonase 1.56 1.5
alpha enolase 1.89 1.37
alpha glucosidase subunit alpha isoform 3 0.64 0.4
ATPase, H+ transporting, lysosomal 70 kDa V1 subunit A 0.30 0.31
ATP citrate lyase beta, mitochondrial 0.33 0.63
Carbonyl reductase [NADPH] 3 3.00 1.56
Chaperonin containing TCP1, subunit 6A 1.34 1.98
chloride intracellular channel 1 1.2 2.12
cofilin 1/2 0.60 0.65
D3-phosphoglycerate dehydrogenase 0.75 0.16
DJ-1 0.54 0.45
EEF1 delta 0.68 0.4
ER-60 protein 2.18 1.56
eukaryotic initiation factor 4A-II 0.35 0.63
eukaryotic translation initiation factor 3 subunit H 0.71 0.49
eukaryotic translation initiation factor 6 4.76 1.57
Ezrin 2.10 4.00
gelsolin precursor 2.73 1.54
glutamate receptor GRIA3 0.24 0.63
glycyl-tRNA synthetase 0.40 0.33
heat shock cognate 71 kDa protein 0.20 0.36
IMMT (mitochondrial inner membrane protein) 3.44 2.32
lamin A/C, isoform CRA_c 0.41 0.47
MAPRE1 protein 0.86 0.4
multidrug resistance-associated protein MGr1-Ag 0.52 0.74
NADH dehydrogenase Fe-S protein 1, 75 kDa 0.56 0.35
nucleoside phosphorylase 1.95 1.31
protein disulfide isomerase associated 6 0.85 0.41
protein disulfide isomerase ER-60 2.13 1.25
RAB8b, member RAS oncogene family 3.16 1.48
RAVER-1 protein 2.17 1.60
splicing factor, arginine/serine-rich 1 0.24 0.71
sterol carrier protein X/2 0.45 0.52
stress-70 protein, mitochondrial precursor
(observed pI 5.9; theoretical pI 5.9)
0.65 0.57
stress-70 protein, mitochondrial precursor
(observed pI 5.6; theoretical pI 5.9)
0.59 0.42
succinate dehydrogenase [ubiquinone] flavoprotein subunit 0.59 0.3
triosephosphate isomerase
(pI observed 6.7; theoretical pI 6.5)
0.70 0.64
thioredoxin domain-containing protein 12 0.64 0.7
RhoA precursor 0.65 0.6
MDAMB231 cells
3-hydroxyisobutyrate dehydrogenase, mitochondrial 0.64 0.73
aldose reductase 1.64 1.40
alpha enolase 0.28 absent
annexin A1
(observed pI 6.6; theoretical pI 6.6)
1.67 1.42
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MDAMB231 breast cancer cells (Continued)
annexin A1
(observed pI 6.4; theoretical pI 6.6)
1.24 3.08
annexin A4 1.52 1.63
cathepsin D precursor 0.55 0.52
cell division cycle protein 42 1.76 2.04
chloride intracellular channel protein 1
(observed pI 5.1; theoretical pI 5.1)
1.58 1.98
chloride intracellular channel protein 1
(observed pI 5.3; theoretical pI 5.1)
1.61 1.97
Cleavage stimulation factor 64 kDa subunit 0.28 0.35
cofilin 1/2 0.62 0.71
complement component 1 Q
subcomponent-binding protein, mitochondrial
0.41 0.63
Cytochrome b-c1 complex subunit 1, mitochondrial 0.71 0.63
Cytochrome c-type heme lyase 0.35 0.37
dihydrolipoamide S-acetyltransferase, component of PDH complex 0.60 0.68
DJ-1 0.34 0.44
elongation factor 1-delta 0.85 0.24
endoplasmic reticulum protein ERp29 precursor 1.36 1.60
eukaryotic translation initiation factor 3 subunit I 0.70 0.73
Ezrin 2.31 1.77
GDP dissociation inhibitor 2 1.6 1.54
gelsolin precursor (identified in 3 spots as fragment) 1.77 1.80
glutathione S-transferase Pi 1.56 1.84
glutathione S-transferase omega-1 1.65 1.57
glycyl-tRNA synthetase 1.91 1.41
GrpE protein homolog 1, mitochondrial precursor 0.67 0.76
heat shock protein 27 1.33 1.57
heterogeneous nuclear ribonucleoprotein F 0.72 0.95
heterogeneous nuclear ribonucleoprotein H1 1.91 2.32
heterogeneous nuclear ribonucleoprotein K 0.41 0.24
heterogeneous nuclear ribonucleoproteins C1/C2 0.56 0.91
high mobility group protein B1 2.59 1.94
interferon-induced GTP-binding protein Mx2 1.24 1.59
Ku70 antigen 0.46 0.35
lactoyl-glutathione lyase 1.82 2.02
lamin-A/C 0.36 0.45
LIM and SH3 domain protein 1 1.73 1.75
macrophage-capping protein (identified in two spots) 2.00 1.98
minichromosome maintenance protein 7 0.44 0.28
moesin 0.53 1.02
MutS homolog 2 0.35 0.16
nucleophosmin 0.61 0.22
peroxiredoxin 2 1.56 1.58
peroxiredoxin 3 1.63 1.81
plexin-D1 precursor 0.30 0.53
pre-mRNA-processing factor 19 0.76 0.48
prohibitin 1.75 1.59
proliferating cell nuclear antigen 0.15 0.49
proteasome activator complex subunit 1 1.20 1.40
proteasome activator complex subunit 3 0.49 0.39
protein NDRG1 1.69 1.58
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MDAMB231 breast cancer cells (Continued)
putative ATP-dependent Clp protease
proteolytic subunit, mitochondrial
0.59 0.76
Ran-specific GTPase-activating protein 1.54 1.66
Ras GTPase-activating protein-binding protein 1 0.54 0.48
reticulocalbin-1 precursor
(identified in two spots as fragment)
0.47 0.64
reticulocalbin-1 precursor 0.58 0.78
stomatin-like protein 2 0.64 0.52
stress-70 protein, mitochondrial
(observed pI 5.9; theoretical pI 5.9)
0.61 0.74
stress-70 protein, mitochondrial precursor
(observed pI 5.4; theoretical pI 5.9)
0.59 0.42
synaptic vesicle membrane protein VAT-1 homolog 5.14 4.55
RhoA precursor 0.49 0.65
TRAP1 1.54 1.76
triosephosphate isomerase
(pI observed 6.2; theoretical pI 6.5)
2.37 2.14
triosephosphate isomerase
(pI observed 6.5; theoretical pI 6.5)
0.77 0.59
tropomyosin 1 alpha chain isoform 4 0.31 0.44
vinculin 2.12 2.69
zyxin 2.39 0.82
The cell treatment occurred with either 8 μg/mL lovastatin lactone or hydroxy acid for 48 hours. The factor change is presented below with values above 1
representing an increase and values below 1 representing a decrease in protein expression as compared with controls. In some cases (annexin 1, chloride
intracellular channel protein 1, stress-70 protein, triose phosphate isomerase) more then one spot was assigned to one protein. This happens when proteins
undergo a post-translational modification as indicated by a shift in the spot’s isoelectric point (pI). In these cases, an observed and a theoretical pI values were
provided.
Figure 3 Western blot analysis of proteins involved in small GTPase-mediated cell signaling. Breast cancer cell lines MDAMB231 and
MDAMB468 were treated with 8 μg/mL lovastatin lactone (Lova Lac) or lovastatin acid (Lova Ac) for 48 hours. For key proteins, western blot
analysis was performed based on MDAMB231 cell extracts (for Ras homolog gene family member A (RhoA), cell division cycle 42 (CDC42) and
GTPase-activating protein SH3-domain-binding protein 1 - phospho form (pG3BP1)), otherwise both cell lines are shown. Densitometry data were
normalized based on the amount of b-actin. Data are presented as means ± standard deviations (n = 3) *P < 0.05;**P < 0.05; ***P < 0.001). Gel
images were cropped to improve the clarity and conciseness of the presentation. GDI-2, Rho GDP dissociation inhibitor 2.
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In both cell lines, lovastatin treatment was accompanied
by the loss of cell viability. Functional clustering facili-
tated the identification and subsequent inclusion of a
large group of proteins related to the apoptosis signal-
ing. These included: TNF type 1 receptor-associated
protein (TRAP-1), 70 kDa subunit of Ku antigen (Ku70),
disulfide isomerase ER-60, DJ-1 (PARK-7; Figure 5),
cofilin 1/2, heat shock 27 kDa, HMGB1, glutathione S-
transferase Pi, annexins A1 and A4, and nucleophosmin
(Table 1).
Cellular metabolism
Lovastatin treatment altered the expression of proteins
involved in the regulation of metabolic processes such as
pentose-phosphate pathway (NADP metabolic process):
3-hydroxyisobutyrate dehydrogenase, 6-phosphoglucono-
lactonase, triosephosphate isomerase 1; glycolysis: triose-
phosphate isomerase 1, alpha enolase, dihydrolipoamide
S-acetyltransferase; and tricarboxylic acid cycle activity as
indicated by decreased expression of succinate dehydro-
genase (ubiquinone) flavoprotein subunit (SDHA) and
dihydrolipoamide S-acetyltransferase. ATP citrate lyase,
Figure 4 Western blot analysis of proteins involved in regulation of the cell cycle including the modulation of the E2F1-Rb activity.
Breast cancer cell lines MDAMB231 and MDAMB468 were treated with 8 μg/mL lovastatin lactone (Lova Lac) or lovastatin acid (Lova Ac) for 48
hours. Western blot analysis of prohibitin was performed based on MDAMB231 cell extracts, otherwise both cell lines are shown. Densitometry
data were normalized based on the amount of b-actin. Data are presented as means ± standard deviations (n = 3) *P < 0.05;**P < 0.05; ***P <
0.001. Gel images were cropped to improve the clarity and conciseness of the presentation. HMGB1, high-mobility group box 1; MCM7,
minichromosome maintenance protein 7; MSH2, MutS homolog 2.
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downregulated as well (Table 1 and Figure 2b).
Lovastatin induced oxidative stress
The expression of ROS scavengers peroxiredoxin 2 and
peroxiredoxin 3 was upregulated, while the expression
of a protein related to the family of thioredoxins, the
thioredoxin domain-containing protein 12, was down-
regulated (Table 1). An increase in expression levels of
two isoforms of glutathione S-transferase, GST-Pi and
GST omega-1, was observed (Table 1). Both of these
isoforms are active in the detoxification of ROS-induced
damage (Figure 2b).
Correlation of proteomic data with western blot protein
expression analysis
In order to confirm the two-dimensional gel electro-
phoresis proteomics mass spectrometry data, western
blot analysis was performed on selected proteins, the
results of which are presented in Figures 3 to 5. When
not performed on both cell lines, the analysis was per-
formed only on the more sensitive of the two, the
Figure 5 Western blot analysis of proteins involved in regulation of apoptosis and AKT-signaling. Breast cancer cell lines MDAMB231 and
MDAMB468 were treated with 8 μg/mL lovastatin lactone (Lova Lac) or lovastatin acid (Lova Ac) for 48 hours. For key proteins, western blot
analysis of phosphatase and tensin homolog (PTEN), pAkt and N-myc downstream regulated gene 1 (NDRG1) was performed based on
MDAMB231 cell extracts, otherwise both cell lines are shown. Densitometry data were normalized based on the amount of b-actin. Data are
presented as means ± standard deviations (n = 3) *P < 0.05;**P < 0.05; ***P < 0.001). Gel images were cropped to improve the clarity and
conciseness of the presentation. PCNA, proliferating cell nuclear antigen.
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blot analysis corresponded well with the results from
the proteomics database search. The expression of the
small GTPases, GDI-2 and CDC42, showed an increase
in MDAMB231 cells. Analysis of the expression of the
membrane-bound, active RhoA surprisingly indicated no
change after exposure to lovastatin lactone, in contrast
to a significant decrease during treatment with lovasta-
tin acid. In the protein group associated with the E2F1
pathway, the expression of E2F1, as well as MSH2,
MCM7 and HMGB1 was more pronounced in the
lovastatin acid group than in the lovastatin lactone treat-
ment group. Time-dependent changes were, again, more
prominent in MDAMB231 than in MDAMB468 cells.
The same specific trend towards higher sensitivity of
MDAMB231 cells to lovastatin acid continued in the
expression of proteins related to Akt signaling. Although
the expression of PTEN increased, its associated regula-
tor protein DJ-1 was down-regulated, as was pAkt itself.
C o n v e r s e l y ,N D R G 1 ,a nA k td o w n s t r e a mt a r g e t ,w a s
upregulated by lovastatin lactone and acid.
Metabonomic analysis
Energy producing pathways: glycolysis and Krebs cycle
As revealed by
1H-NMR, 48 hour incubation of
MDAMB468 cells with 8 μg/mL lovastatin lactone or
lovastatin acid strongly inhibited glycolytic activity by
decreasing the de novo production of
13C-alanine and
13C-lactate. The
13C-lactate concentrations (mean ± stan-
dard deviation) decreased to 41 ± 8% of control (P <
0.001, n = 3) during lovastatin lactone exposure and 56 ±
3% of control (P < 0.005, n = 3) during lovastatin acid
exposure (Table 2 and Figure 6). Lovastatin lactone and
acid also induced a strong reduction in the Krebs cycle
activity, as measured through the
13C-enrichment of
Krebs cycle products, such as glutamine and glutamate.
Concentration of C4-glutamate decreased from 474 ± 72
nmol/g in controls to 91 ± 11 nmol/g in lovastatin lac-
tone (P < 0.001, n = 3) and to 111 ± 17 nmol/g (P <
0.001, n = 3) in lovastatin acid-treated cells (Table 2 and
Figure 6). Furthermore, lovastatin acid reduced the con-
centration of citrate, a direct Krebs cycle intermediate to
30 ± 11% of control (P < 0.005, n = 3, Table 2 and Figure
6). The reduction in the activity of these two major glu-
cose metabolizing processes was accompanied by an
accumulation of intracellular glucose (Table 2 and Figure
6). In regards to surrogate markers for ROS formation,
1H-NMR analysis of cell extracts revealed a highly signifi-
cant decline in total cellular glutathione concentrations
(from 2595 ± 168 nmol/g in controls to 871 ± 72 and
1149 ± 78 nmol/g in lovastatin lactone and acid treated
cells; P < 0.001, n = 3, Table 2 and Figure 6), suggesting
an increase in oxidative damage.
Lipid metabolism
Both lovastatin forms led to similar changes in the lipid
constitution of the cell, causing a reduction in the sig-
nals for cholesterol, choline-containing phospholipids
and fatty acids (Figure 7). However, the changes were
more pronounced in lovastatin lactone-treated cells
where the concentration of total choline-containing
phospholipids decreased to 57 ± 7% (P <0 . 0 0 5 ,n=3 ) ,
cholesterol C18 to 55 ± 6% (P < 0.005, n = 3), choles-
terol C19 to 54 ± 9% (P < 0.05, n = 3), and concentra-
tions of different unsaturated fatty acids declined to 50
to 65% of control values (Table 2 and Figure 7).
Discussion
Although the beneficial effects of HMG-CoA reductase
inhibitors in lowering cholesterol are well established,
their importance in the area of cancer therapeutics is
only now beginning to gain greater recognition
[1,2,10,12]. Normal cells respond to statin inhibition of
HMG-CoA reductase activity through a feedback upre-
gulation of sterol- and lipid-synthesizing gene programs,
including the low-density lipid receptor [30]. Cancer
cells usually exhibit elevated levels of HMG-CoA reduc-
tase and low-density lipid receptor. Thus, cancer cells
are potentially more sensitive than normal cells to the
isoprenoid-depleting effects of statins [31]. In this study,
we used a combination of 2DE-proteomic and NMR-
based metabonomic strategies to further investigate the
molecular mechanisms by which lovastatin exhibits its
reported antitumor activity.
Two estrogen receptor-negative breast cancer cell
lines, MDAMB231 and MDAMB468, were treated for
48 hours with 8 μg/mL lovastatin lactone or lovastatin
Table 2 Intracellular concentrations (nmol/g cell weight)
of
13 C-labeled endogenous metabolites (glycolysis and
TCA cycle intermediates, glucose) and lipid metabolites
(choline-containing phospholipids, cholesterol)
Control Lovastatin lactone Lovastatin
acid
13C-lactate 612 ± 36 252 ± 51** 343 ± 15**
glycolysis int 845 ± 21 369 ± 13*** 467 ± 52***
TCA cycle int 913 ± 232 189 ± 28** 213 ± 56**
glucoseintracell 1918 ± 382 2691 ± 283* 2758 ± 231*
citrate 323 ± 46 98 ± 33*** 153 ± 35**
glutathione 2595 ± 168 871 ± 72*** 1149 ± 78**
choline-PL 3757 ± 534 2158 ± 275** 2672 ± 542*
chol C18+C19 3914 ± 582 2125 ± 289** 2467 ± 351**
The values were calculated based on MDAMB468 cell extracts as assessed by
1H-NMR and
13C-NMR. The cells were incubated with 8 μg/mL lovastatin
lactone or hydroxy acid for 48 hours. Values are presented as means ±
standard deviation of three independent experiments. Significance levels: * P
< 0.05; ** P < 0.005; *** P < 0.001 were determined by analysis of variance
(with post-hoc pairwise multiple comparison Tukey-test). chol, cholesterol;
choline-PL, choline-containing phospholipids; glu, glutamate; glycolysis int,
glycolysis intermediates:
13C-lactate+
13C-alanine, TCA int: TCA cycle
intermediates: (C2 + C3 + C4)-glutamate + (C2 + C3)-glutamine.
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13C-labeled -alanine, -lactate, -glucose and -glutamine signals in MDAMB468 cells treated with 8 μg/
mL lovastatin acid for 48 hours.
13C-NMR spectra with embedded, corresponding
1H-NMR spectra are shown (including citrate at 2.52 + 2.69
ppm). Arrows indicate the direction of signal changes (increase or decrease). Ala, alanine; Gln, glutamine; Glu, glutamine; GSH, total glutathione;
Lac, lactate.
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1H-NMR spectra of MDAMB468 lipid extracts. Cells were treated with 8 μg/mL lovastatin acid for 48 hours. Arrows
indicate the direction of signal changes (decrease). Chol, cholesterol (C18 and C19, CH3); Δ (δ), double bond; F, fatty acid side chain; Fa,F b,
protons in the fatty acid chain; Fmix: -(CH2)n-, tCho, total choline-containing phospholipids.
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and Rb, MDAMB468 does not express either of these.
In regards to their sensitivity to lovastatin, both cell
lines exhibited similar IC50 values. However, in regard
to changes detected by 2DE, MDAMB231 cells demon-
strated alterations in a larger number of proteins and
presumably a greater sensitivity to lovastatin. After
exposure to lovastatin acid or lactone, the majority of
proteins detected did not show differences in changes
between the two treatment groups. This may partly be
supported by previous data, which shows that in a cell
culture medium, 80% of the lactone prodrug converts to
the acid form within 9 hours and achieves complete
conversion within 24 hours [32]. Western blot analysis
further confirmed that the observed lovastatin-induced
changes in protein expression were more pronounced in
the MDAMB231 than the MDAMB468 cells. This sug-
gests that their phenotypic differences (e.g. PTEN, Rb
expression) may be responsible for the stronger
response to lovastatin. In MDAMB231 cells, the
differences between the lovastatin lactone and lovastatin
acid were more distinct, in general with lovastatin acid
exhibiting greater effects, especially on the GTPase, E2F
and AKT signaling pathways (Figures 3, 4, 5 and Figure
8).
Inhibition of the mevalonate pathway by lovastatin
suppresses the synthesis of two substrates that provide
the isoprenoid moieties for post-translational modifica-
tions of diverse proteins: farnesyl and geranylgeranyl
diphosphates [33]. This suppresses the essential post-
translational processing of proteins regulating cell prolif-
eration and viability [34]. Examples are the Ras and Rho
proteins, which require attachment of FPP or GGPP
groups prior to their activation and delocalization to the
plasma membrane [35]. Several groups have reported
that the addition of mevalonate pathway intermediates
such as mevalonate, GGPP and partially FPP, can dimin-
ish the pro-apoptotic effects of statins [36]. Also, the
addition of mevalonate (at 100-fold the lovastatin con-
centration) has been shown to release the cells from the
Figure 8 Schematic diagram summarizing the effects of lovastatin lactone and acid on signaling pathways as found in the present
study. The solid arrows mark the directional change of proteins (up- or down-regulation). Doted arrows mark hypothesized change in protein
expression/activity. CDC42, cell division cycle 42; G3BP1, GTPase-activating protein SH3-domain-binding protein 1; GDI-2, Rho GDP dissociation
inhibitor 2; LIMK, LIM domain kinase; MAPK, mitogen-activated protein kinase; MCM7, minichromosome maintenance protein 7; MSH2, MutS
homolog 2; NDRG1, N-myc downstream regulated gene 1; p21, cyclin-dependent kinase inhibitor 1A; PCNA, proliferating cell nuclear antigen;
PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; Rb, retinoblastoma protein; RhoA, Ras homolog gene family member A.
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entry into late G1, S and G2/M phases [37]. This points
to the predominant role of protein geranylgeranylation
in statin-induced apoptosis in cancer cells [10,38,39]. In
our study, the addition of mevalonate and GGPP
reversed the effects of lovastatin on the inhibition of
breast cancer cell proliferation, whereas FPP could only
p a r t i a l l yr e s c u ec e l l sf r o mt h ea n t i p r o l i f e r a t i v ee f f e c to f
lovastatin. Although FPP lies upstream of GGPP in the
mevalonate pathway, the addition of FPP would not be
capable of restoring protein geranylgeranylation because
a second molecule, isopentenyl pyrophosphate (PPi), is
required for the conversion of FPP to GGPP. Isopente-
nyl PPi is also depleted by statin exposure, and is there-
fore unavailable to the statin-treated cells.
Small GTPase-proteins are frequently discussed tar-
gets of statins [27,28]. Our proteomics data identified
RhoA, a protein implicated in the control of cell
growth, apoptosis [40] and tumorigenesis [41]. We
demonstrated that the translocalization of RhoA in
MDAMB231 cells to the membrane was suppressed by
lovastatin (Figures 3 and 8). We also observed an
increased expression of GDI-2, which stabilizes the
non-activated form of RhoA and prevents its relocaliza-
tion to the membrane and subsequent activation by
GGPP (Figure 8). In addition, lovastatin acid treatment
changed the expression of Ras-GTPase activating bind-
ing protein G3BP1 (down-regulation of its unmodified
and its active phospho form) and CDC42 (upregulated;
Figures 3 and 8). The latter acts as a signal transduction
convergence point in intracellular signaling networks
mediating multiple signaling pathways, including tyro-
sine kinase receptors, heterodimeric G-protein coupled
receptors and cytokine receptors [42]. G3BP1 directly
associates with the SH3 domain of GTPase-activating
protein, functioning as an effector of Ras [43]. More-
over, we identified a decrease of cofilin 1/2, a CDC42
and LIM kinase target protein [44] (Figure 8). Post-
translational modification analysis (using the ProteinPi-
lot and special factors: phosphorylation emphasis, para-
gon search method) revealed that the cofilin form
decreased by lovastatin was phosphorylated at S3, S8
and T16. This reduction of the phosphorylated cofilin is
in accordance with previous reports [45].
Regulation of the cell cycle including the modulation
of Rb-E2F1 activity is the second major signaling path-
way affected by lovastatin treatment in breast cancer
cells (Figure 8). PCNA, a cell proliferation marker and a
control point for DNA repair [46], was found to be sig-
nificantly down-regulated by lovastatin in both cell lines.
Its downregulation has been proven to correlate with
the overexpression of p21 and is followed by a G1 arrest
in cells [47]. The latter has been shown to occur in cells
treated with statins [12,37,48,49], making them popular
as agents for reversible synchronization of cells in the
G1 phase of the cell cycle [37].
The upregulation of the cell-cycle regulatory protein
prohibitin, a tumor suppressor protein able to co-loca-
lize with Rb and suppress the E2F1 and p53 transcrip-
tional activity [50], is another novel finding of our study.
Despite the observation that prohibitin is upregulated in
both cell lines following lovastatin treatment (to a
higher degree in MDAMB231 cells), an expected down-
regulation of E2F1 only occurred in Rb-positive
MDAMB231 cells. Therefore, while acting synergistically
with Rb in the suppression of E2F1, prohibitin does not
seem to impair E2F1 expression alone. As for the down-
stream targets in the E2F-mediated pathway, we identi-
fied changes in both MCM7 [51] and MSH2 [52].
Although MCM7 belongs to the cell cycle DNA check-
points, MSH2 is a representative member of MMR sys-
tems. The expression of both of these was significantly
suppressed by lovastatin. Interestingly, the suppression
occurred in both cell lines, suggesting that it may not be
mediated exclusively through E2F1 reduction, and that
perhaps other regulatory pathways are also affected by
lovastatin.
Statin-treated breast cancer cells die through apoptosis
[12,48,49]. It was therefore not surprising that a large
number of identified proteins was associated with the
programmed cell death pathway. In addition to prohibi-
tin, RhoB and cofilin 1/2, there was also suppression of
TRAP-1 and Ku70 expression. Both of these proteins
protect the cells from apoptosis and oxidative stress
[53,54]. These data comply with previous reports sug-
gesting that increased oxidative stress may be a cause of
statin-induced cytotoxicity in breast cancer [13,49].
Recently, it has been shown that fluvastatin and simvas-
tatin enhance NO levels and increase iNOS RNA and
protein expression in breast cancer MCF-7 cells, indicat-
ing that iNOS-mediated NO is responsible, in part, for
the proapoptotic, tumoricidal, and antiproliferative effect
of statins [14]. Furthermore, the cell death of MCF-7
cells incubated with N-acetyl-L-cysteine plus statins
could almost be reversed [49], supporting our results
that oxidative stress plays an important role in the cell
death induced by statins.
In terms of metabolic changes, the downregulation of
glycolytical enzymes triosephosphate isomerase, alpha-
enolase and dihydrolipoamide acetyltransferase and tri-
carboxylic acid cycle enzymes such as SDHA represent
potential pathways by which lovastatin may induce cell
death through the suppression of energy-producing
pathways. Glycolysis is the primary energy-producing
pathway in cancer cells and is therefore a highly valu-
able target in anti-cancer therapy [55]. The changes in
enzyme expressions correlate with the NMR-based
metabolic profiles: decreased production of de novo
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13C-alanine and C4-glutamate and accumu-
lation of intracellular glucose (Figures 6 and 8).
Due to its close relation to anaerobic glycolysis [56],
we chose to investigate the role of the protein kinase
Akt. A downregulation of the active p-Akt form was
detected in both cell lines. One possible mechanism of
Akt deactivation involves its regulation by PTEN, inhi-
biting the ability of phosphatidylinositol 3-kinase to
phosphorylate Akt [57]. As expected, we observed an
i n d u c t i o no fP T E Ne x p r e s s i o nb yl o v a s t a t i ni nt h e
PTEN-expressing MDAMB231 cell line (Figures 5 and
8). The induction was more pronounced when the cells
were treated with the lovastatin acid than with its lac-
tone form. PTEN itself is known for tumor suppression
and frequently mutates in a wide variety of cancers and
is functionally involved in their metastatic advancement
[58]. The ability of statins to stimulate the overexpres-
sion of PTEN and their importance for therapeutic and
preventative uses in cancer, diabetes mellitus and cardi-
ovascular disease has been recognized in the past
[59-61]. To date, several mechanisms have been dis-
cussed including the transcriptional activation of peroxi-
some proliferator-activated receptor and upregulation of
the sterol response element-binding protein [59-61]. In
our proteomics data we have identified a protein
affected by lovastatin described in the literature as a
negative regulator of PTEN [62,63]. This protein, known
as DJ-1/PARK7, is an oncogene that cooperates with H-
Ras and transforms cells by increasing cell proliferation
and resistance to cell cycle arrest [64]. In breast cancer,
overexpression of DJ-1 positively correlates with phos-
phorylated Akt and poor disease prognosis [62]. In both
of our breast cancer cell lines (PTEN expressing
MDAMB231 and PTEN lacking MDAMB468), lovastatin
acid successfully decreased the expression of DJ-1 (Fig-
ures 5 and 8). Conversely, lovastatin lactone, previously
shown to induce PTEN in a less effective manner than
the acid form, failed to decrease DJ-1 expression. This
result confirms that the expression of DJ-1 is correlated
with the expression of PTEN and suggests that DJ-1 is
able to regulate the activity of the Akt kinase even in
the absence of PTEN. DJ-1 and PTEN synergistically
lowered the expression of the active pAkt form, but
only when cells were treated with lovastatin acid. Our
results suggest that DJ-1, and not PTEN, might be the
key regulator of pAkt expression in lovastatin-treated
breast cancer cells. This hypothesis will require further
evaluation. The influence of lovastatin is also detected
downstream of the DJ-1/PTEN-regulated Akt pathway
on the expression of yet another clinically important
protein, NDRG1. NDRG1 not only plays an important
role in metastatic tumor progression, it has also been
observed to slow the advancement of breast cancer in a
clinical study and, interestingly, to be regulated by
PTEN through an Akt-dependant pathway [65]. The
downregulation of NDRG1 occurred in cells treated
with either lovastatin lactone or lovastatin acid, indicat-
ing that its expression might be regulated through path-
ways other than the inhibition of pAkt.
Correlation between metabonomic and proteomic data
Dihydrolipoamide S-acetyltransferase and ATP citrate
lyase are enzymes that are involved in the production of
acetyl-CoA. A reduction in their expression decreases
production of acetyl-CoA. This has a negative effect on
fatty acid and cholesterol synthesis. Our NMR data
revealed a significant reduction of choline-containing
phospholipids, fatty acids and cholesterol concentrations
as a result of lovastatin treatment. Additionally, we iden-
tified a transporter, the sterol carrier protein-X/2, which
is not only involved in cholesterol, fatty acids and phos-
pholipids trafficking [66], but also has a high affinity for
isoprenyl pyrophosphates (GGPP, FPP, GPP) [67]. Its
downregulation suggests that both, the production of
isoprenylated intermediates and their transport are
influenced by lovastatin.
Conclusions
Overall, our data indicated that in the studied breast
cancer cells lovastatin lactone and acid affect small
GTPase, E2F and AKT signaling pathway (Figure 8).
Lovastatin-treated breast cancer cells showed changes in
the activity of various small GTPases, primarily through
the inhibition of the isoprenylation of RhoA. This inhi-
bition is partially mediated by the stabilization of the
non-active RhoA form, which is achieved through an
increase in expression of Rho inhibitor GDI-2. Lovasta-
tin decreased the activity of G3BP1, a GTPase that is
over-expressed in a number of human malignancies. It
can be speculated that this may constitute a novel target
for the sensitization of cancer cells to genotoxic stress.
Lovastatin also modulated the E2F1 pathway by regulat-
ing the expression of prohibitin and Rb and resulted in
changes of the E2F-downstream targets MCM7 and
MSH2. The deactivation of the AKT-pathway through
an upregulation of PTEN and down-regulation of DJ-1
represents an additional target by which lovastatin possi-
bly regulates tumor cell survival and progression. It is
important to mention the induction of oxidative stress,
suppression of glycolytic and Krebs cycle activity as well
as lipid biosynthesis as metabolic consequences to lovas-
tatin exposure.
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